Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 545Lung Neoplasms 240Small Cell Lung Carcinoma 106Mesothelioma, Malignant 57Adenocarcinoma of Lung 41Mesothelioma 35Neoplasms 27Neoplasm Metastasis 25Colorectal Neoplasms 22Carcinoma 17Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 15Adenocarcinoma, Bronchiolo-Alveolar 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Stomach Neoplasms 12Pancreatic Neoplasms 12Non-Squamous Non-Small Cell Lung Cancer 12Head and Neck Neoplasms 12Pleural Effusion, Malignant 8Melanoma 8Breast Neoplasms 8Sarcoma 7Extensive Stage Small Cell Lung Cancer 7Triple Negative Breast Neoplasms 6Thymoma 6Solitary Fibrous Tumor, Pleural 6NSCLC 6Endometrial Neoplasms 6Drug-Related Side Effects and Adverse Reactions 6Colonic Neoplasms 6

Interventions

Gemcitabine 2ruxolitinib 1rucaparib 1pemigatinib 1pembrolizumab 1motexafin gadolinium 1abiraterone 1Watchful Waiting 1Vorinostat 1Trastuzumab 1Tinzaparin 1TTI-621 1Rituximab 1Paclitaxel 1Nivolumab 1Ipilimumab 1In Situ Hybridization, Fluorescence 1INCB057643 1Fentanyl 1Epoetin Alfa 1Doxorubicin 1Docetaxel 1Cisplatin 1CTLA-4 Antigen 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Cisplatin × Thoracic × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡